BTK and melanoma: Ibrutinib treatment also resulted in a significant reduction in MDSCs (expressed BTK) in wild-type mice bearing B16F10 melanoma tumors, but not in X-linked immunodeficiency mice (XID) harboring a Bruton tyrosine kinase (BTK) mutation [89], suggesting that ibrutinib may be a potential therapeutic agent to reduce MDSCs in cancer types other than chronic lymphatic leukemia (CLL).